First, although Eva1c/EVA1C emerged as a significantly regulated splicing target upon NAD+ precursor treatment, we did not examine whether knockdown or knockout of Eva1c alone is sufficient to induce abnormal ASEs similar to those observed in tauopathy models. The gene discussed is EVA1C; the disease is tauopathy.